In the Face of Adversity: Flexible Trial Strategies for Small Biotechs

Discover how Ergomed’s adaptable approach enabled a small biotech to advance its Phase I/II Clinical Trial for Advanced Clear Cell Renal Cell Carcinoma (RCC), evaluating an innovative oral CXCR4 inhibitor.

 
Faced with costly delays, this startup relied on Ergomed’s expertise to create and rapidly launch a concurrent “sister study”, maximizing efficiency and maintaining timelines. Learn how Ergomed’s quick thinking and strategic execution provided essential support, helping the study proceed smoothly and gathering critical data for future development. Download the full case study to see how Ergomed empowers small biotechs to thrive in challenging clinical trials.  

Please fill out the form to view the content

"*" indicates required fields

Please enter your details to get access to the resource

By submitting this form, you consent to your personal data submitted in the form being processed in alignment with our Online Privacy and Cookies policy. Your personal data will be processed to facilitate your request and may be used for sending you additional marketing and business development-related information about Ergomed, its affiliates, and our services. You can withdraw your consent anytime by messaging marketing@ergomedgroup.com, and we will promptly remove your data from our records. For more information about how we will process your personal data and your rights, please see our Online Privacy and Cookies policy.
This field is for validation purposes and should be left unchanged.